BioCentury
ARTICLE | Clinical News

AGT-182: Phase I started

July 13, 2015 7:00 AM UTC

ArmaGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1 and 3 mg/kg IV AGT-182 once weekly for 8 weeks in about 12 patients. The trial start triggered an undisclosed milestone p...